NCT06657755Completed
Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients
A Study to Evaluate ENPP1 Expression and Its Role in Immune Evasion and Chemoresistance in Bladder Cancer
Source: ClinicalTrials.gov · Last updated 24 Oct 2024
Brief summary (registry, in English)
This study aims to investigate the role of ENPP1 in bladder cancer (BC), specifically focusing on its impact on immune evasion, chemoresistance, and prognosis. The study will analyze gene expression data from clinical samples and use various laboratory techniques, including RNA sequencing, qRT-PCR, and immunohistochemistry, to assess ENPP1's expression levels. In addition, the research will explore the relationship between ENPP1 and immune cell infiltration, along with its correlation with patient survival outcomes. By identifying ENPP1's contribution to cancer progression and treatment resistance, the study aims to discover potential therapeutic targets for improving bladder cancer treatment strategies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 12 (actual)
- First submitted
- 21 Oct 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- Lanzhou University Second Hospital
- Diseases
- Bladder cancer
- NCT number
- NCT06657755
What you commit to
- Study type: Observational
- Participants enrolled: 12
- From 1 Jun 2024 to the primary completion date, 1 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with ENPP1 inhibitors or similar targeted therapies.
Other illness
- History of other malignancies within the past 5 years, excluding non-melanoma skin cancer or in situ carcinoma.
- Active or uncontrolled infections.
- Known autoimmune disorders or conditions requiring immunosuppressive therapy.
Other
- Pregnant or breastfeeding women.
- Inability to comply with the study protocol or procedures.
Who the study is looking for
- Adults aged 18 years or older.
- Histologically confirmed diagnosis of bladder cancer.
- Measurable disease as per RECIST criteria.
- Adequate organ function as defined by laboratory tests (e.g., liver, kidney, and hematologic function).
- ENPP1 expression level determined via biopsy or previous analysis.
- Written informed consent provided.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lanzhou University Second Hospital Coordinator of this site? Confirm its status | Lanzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.